ES2139746T3 - Heteroaril cicloalquenil hidroxiureas. - Google Patents

Heteroaril cicloalquenil hidroxiureas.

Info

Publication number
ES2139746T3
ES2139746T3 ES94919852T ES94919852T ES2139746T3 ES 2139746 T3 ES2139746 T3 ES 2139746T3 ES 94919852 T ES94919852 T ES 94919852T ES 94919852 T ES94919852 T ES 94919852T ES 2139746 T3 ES2139746 T3 ES 2139746T3
Authority
ES
Spain
Prior art keywords
sub
alkyl
chlorine
fluorine
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919852T
Other languages
English (en)
Inventor
Akiyoshi Kawai
Rodney W Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2139746T3 publication Critical patent/ES2139746T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)

Abstract

CIERTOS NUEVOS COMPUESTOS DE HIDROXIUREA DE CICLOALQUENILO DE HETEROARILO QUE TIENEN LA CAPACIDAD DE INHIBIR LA ENZIMA 5LIPOXIGENASA Y QUE TIENEN LA FORMULA (I) Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE CADA R{SUP,1}, INDEPENDIENTEMENTE, ES HIDROGENO, HIDROXI, CLORO, FLUOR, ALQUILO C{SUB, 1}-C{SUB, 4}, ALCOXI C{SUB, 1}-C{SUB, 4}, HALOALQUILO C{SUB, 1}-C{SUB, 4} O HALOALCOXI C{SUB, 1}-C{SUB, 4}; R{SUP,2} ES HIDROGENO O ALQUILO C{SUB, 1}-C{SUB, 4}; R{SUP,3} ES HIDROGENO, CLORO, FLUOR O ALQUILO C{SUB, 1}-C{SUB, 4}; X ES O, S, SO O SO{SUB,2}; Z ES METILENO O ETILENO; A ES UN RADICAL DIVALENTE DERIVADO DE FURANO, TIOFENO, PIRIDINA, BENZOFURANO, BENZOTIOFENO O QUINOLINA, O UNO DE ESTOS GRUPOS QUE TIENE UN SUSTITUYENTE SELECCIONADO DE CLORO, FLUOR, ALQUILO C{SUB, 1}C{SUB, 4}, ALCOXI C{SUB, 1}-C{SUB, 4}, HALOALQUILO C{SUB, 1}C{SUB, 4} Y HALOALCOXI C{SUB, 1}-C{SUB, 4}; N ES 1, 2, O 3; Y M ES HIDROGENO O UN CATION FARMACEUTICAMENTE ACEPTABLE. ESTOS COMPUESTOS SON UTILES EN EL TRATAMIENTO O ALIVIO DE ENFERMEDADES INFLAMATORIAS, ALERGIA Y ENFERMEDADES CARDIOVASCULARES EN MAMIFEROS Y COMO EL INGREDIENTE ACTIVO EN COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE TALES CONDICIONES.
ES94919852T 1993-07-20 1994-07-05 Heteroaril cicloalquenil hidroxiureas. Expired - Lifetime ES2139746T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17940193 1993-07-20

Publications (1)

Publication Number Publication Date
ES2139746T3 true ES2139746T3 (es) 2000-02-16

Family

ID=16065226

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919852T Expired - Lifetime ES2139746T3 (es) 1993-07-20 1994-07-05 Heteroaril cicloalquenil hidroxiureas.

Country Status (11)

Country Link
US (1) US5665768A (es)
EP (1) EP0710233B1 (es)
JP (1) JPH08511029A (es)
AT (1) ATE185563T1 (es)
CA (1) CA2167715C (es)
DE (1) DE69421183T2 (es)
DK (1) DK0710233T3 (es)
ES (1) ES2139746T3 (es)
FI (1) FI943420A7 (es)
GR (1) GR3032238T3 (es)
WO (1) WO1995003292A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016054A1 (en) * 1994-11-18 1996-05-30 Pfizer Pharmaceuticals Inc. Cycloalkenyl-n-hydroxyureas
HK1049443A1 (zh) * 1999-11-12 2003-05-16 Angiotech Pharmaceuticals, Inc. 用放射活性疗法和细胞循环抑制剂联合治疗疾病的组合物和方法
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
CN101134119A (zh) 2002-05-24 2008-03-05 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334975C (en) * 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
GB9025514D0 (en) * 1990-11-23 1991-01-09 Wellcome Found Anti-inflammatory compounds
JP3007138B2 (ja) * 1990-11-27 2000-02-07 ファイザー製薬株式会社 新規なヒドロキサム酸とｎ―ヒドロキシ尿素誘導体およびそれらの組成物
JPH0717612B2 (ja) * 1991-06-28 1995-03-01 ファイザー製薬株式会社 新規なテトラヒドロベンズアゼピン誘導体
JP2989951B2 (ja) * 1991-10-25 1999-12-13 ファイザー製薬株式会社 新規なシクロアルキル尿素誘導体および組成物
US5521212A (en) * 1991-12-13 1996-05-28 Pfizer Inc. Cyclopropyl N-hydroxyurea and N-hydroxyacetamides which inhibit lipoxygenase
US5169854A (en) * 1992-02-26 1992-12-08 Abbott Laboratories N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity
US5187192A (en) * 1992-03-13 1993-02-16 Abbott Laboratories Cyclobutyl derivatives having lipoxygenase inhibitory activity

Also Published As

Publication number Publication date
FI943420A0 (fi) 1994-07-19
GR3032238T3 (en) 2000-04-27
US5665768A (en) 1997-09-09
EP0710233B1 (en) 1999-10-13
FI943420L (fi) 1995-01-21
CA2167715C (en) 1998-10-06
EP0710233A1 (en) 1996-05-08
DE69421183D1 (de) 1999-11-18
CA2167715A1 (en) 1995-02-02
DE69421183T2 (de) 2000-01-20
JPH08511029A (ja) 1996-11-19
DK0710233T3 (da) 2000-01-03
FI943420A7 (fi) 1995-01-21
WO1995003292A1 (en) 1995-02-02
ATE185563T1 (de) 1999-10-15

Similar Documents

Publication Publication Date Title
DK0971888T3 (da) 2-alkyl-19-nor-vitamin D-forbindelser
ES2160525B1 (es) Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3
DK1268416T3 (da) 2-alkyliden-19-nor-vitamin-D-forbindelser og deres terapeutiske anvendelser
DK0970047T3 (da) 2-Alkyliden-19-nor-vitamin D-forbindelser
PA8608201A1 (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular
ES2069410T3 (es) Nuevos derivados del acido hidroxamico y n-hidroxiurea y su uso.
ATE240955T1 (de) 4-substituierte beta-carboline als immunomodulatoren
ES2118557T3 (es) Compuestos de isoxazolina como inhibidores de la liberacion de tnf.
AR023823A1 (es) Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos.
AR034858A1 (es) Compuestos elevadores de abca-1,composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
MX9306704A (es) Quinuclidinas substituidas.
GT200400136A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular.
MX2026000537A (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
ES2159717T3 (es) Derivados de acido 5-(piperidinil-1 sustituido en posicion 4)-3-aril-pentanoico como antagonistas de los receptores de taquiquinina.
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
NO20014241L (no) C16-umettede FP-selektive prostaglandinanaloger
ES2121218T3 (es) Fenoxifenilciclopentenilhidroxiureas.
KR970032863A (ko) 활성산소-유리기 소거제
WO2023150790A3 (en) Novel and highly selective sars-cov-2 mpro inhibitors
ES2063578T3 (es) Derivados del acido hidroxamico y de n-hidroxiurea inhibidores de la lipoxigenasa.
BR9909267A (pt) C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos
ES2054653T3 (es) Un procedimiento para preparar un compuesto quimico.
ES2138211T3 (es) N-hidroxiureas como agentes antiinflamatorios.
MX2024014168A (es) Antagonistas de at2r y usos de estos
ATE167180T1 (de) Cycloalkylhydroxyharnstoffe und ihre verwendung als lipoxy-genase-inhibitoren

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710233

Country of ref document: ES